Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives

被引：14

作者：

Ding, Bingwen ^{[1
,2
,3
]}

Zhu, Zhu ^{[1
,2
,4
]}

Guo, Cong ^{[1
,2
,3
]}

Li, Jiaxin ^{[1
,2
,3
]}

Gan, Yong ^{[1
,2
,3
,5
]}

Yu, Miaorong ^{[1
,2
,3
]}

机构：

[1] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China

[2] Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China

[3] Univ Chinese Acad Sci, Beijing 100049, Peoples R China

[4] Henan Univ, Sch Pharm, Kaifeng 475004, Peoples R China

[5] Natl Inst Food & Drug Control, NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipie, Beijing 100050, Peoples R China

来源：

ACTA PHARMACEUTICA SINICA B | 2024年 / 14卷 / 05期

基金：

中国国家自然科学基金;

关键词：

Oral peptides; Diabetes; Delivery platforms; Insulin; Glucagon-like peptide-1; Biodistribution; Biological barriers; Targeted delivery; MUCUS-PERMEATING NANOPARTICLES; DRUG-DELIVERY-SYSTEM; INSULIN DELIVERY; POLYMERIC NANOPARTICLES; INTESTINAL PERMEABILITY; ABSORPTION ENHANCEMENT; ENHANCING MECHANISM; PROTEASE INHIBITORS; MULTIPLE BARRIERS; RECEPTOR AGONISTS;

D O I：

10.1016/j.apsb.2024.02.019

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Diabetes, characterized by hyperglycemia, is a major cause of death and disability worldwide. Peptides, such as insulin and glucagon-like peptide-1 (GLP-1) analogs, have shown promise as treatments for diabetes due to their ability to mimic or enhance insulin's actions in the body. Compared to subcutaneous injection, oral administration of anti-diabetic peptides is a preferred approach. However, biological barriers significantly reduce the efficacy of oral peptide therapeutics. Recent advancements in drug delivery systems and formulation techniques have greatly improved the oral delivery of peptide therapeutics and their efficacy in treating diabetes. This review will highlight (1) the benefits of oral anti- diabetic peptide therapeutics; (2) the biological barriers for oral peptide delivery, including pH and enzyme degradation, intestinal mucosa barrier, and biodistribution barrier; (3) the delivery platforms to overcome these biological barriers. Additionally, the review will discuss the prospects in this field. The information provided in this review will serve as a valuable guide for future developments in oral anti-diabetic peptide therapeutics.

引用

页码：2006 / 2025

页数：20